FDA Releases Guidance on Premarket Notification Submissions and Performance Assessment

Summary

The Food and Drug Administration (FDA) has announced the availability of a new guidance document that outlines how the agency will assess its performance in the premarket notification program, which is tied to medical device user fees, and how this will impact its review clock and performance assessment.